Search Results - jorge+luis+espinoza-calderon

2 Results

Sort By:

Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma

This technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies...

Published: 8/12/2024 | Inventor(s): Richard Childs, Jorge Luis Espinoza-Calderon, Maria Berg

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Oncology

Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma

Published: 8/12/2024 | Inventor(s): Richard Childs, Jorge Luis Espinoza-Calderon, Maria Berg

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Human Cell Lines, TherapeuticArea > Oncology